People: United Therapeutics Corp (UTHR.O)
UTHR.O on Nasdaq
66.04USD
1:33pm EDT
66.04USD
1:33pm EDT
Price Change (% chg)
$-1.57 (-2.32%)
$-1.57 (-2.32%)
Prev Close
$67.61
$67.61
Open
$67.58
$67.58
Day's High
$67.58
$67.58
Day's Low
$65.25
$65.25
Volume
458,653
458,653
Avg. Vol
835,537
835,537
52-wk High
$69.65
$69.65
52-wk Low
$42.12
$42.12
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Martine Rothblatt |
58 | 1996 | Chairman of the Board, Chief Executive Officer |
Roger Jeffs |
51 | 2002 | President, Chief Operating Officer, Director |
Christopher Patusky |
48 | 2007 | Lead Independent Vice Chairman of the Board |
John Ferrari |
58 | 2006 | Chief Financial Officer, Treasurer |
Paul Mahon |
49 | 2003 | Executive Vice President, General Counsel, Corporate Secretary |
Raymond Dwek |
70 | 2002 | Director |
Raymond Kurzweil |
64 | 2002 | Non-Independent Director |
Christopher Causey |
49 | 2003 | Independent Director |
Richard Giltner |
48 | 2009 | Independent Director |
R. Paul Gray |
48 | 2003 | Independent Director |
Louis Sullivan |
79 | 2002 | Independent Director |
Tommy Thompson |
71 | 2010 | Independent Director |
Biographies
| Name | Description |
|---|---|
Martine Rothblatt |
Dr. Martine A. Rothblatt, Ph.D., J.D., M.B.A. is Chairman of the Board, Chief Executive Officer of United Therapeutics Corp. She founded United Therapeutics in 1996 and has served as Chairman and Chief Executive Officer since its inception. Prior to United Therapeutics, she founded and served as Chairman and Chief Executive Officer of Sirius Satellite Radio. She is a co-inventor on three of patents pertaining to treprostinil. She has served as a United Therapeutics director since 1996. |
Roger Jeffs |
Dr. Roger Jeffs, Ph.D. is President, Chief Operating Officer, Director of United Therapeutics Corp. He received his undergraduate degree in chemistry from Duke University and his Ph.D. in pharmacology from the University of North Carolina. Dr. Jeffs joined United Therapeutics in September 1998 as Director of Research, Development and Medical. He was promoted to Vice President of Research, Development and Medical in 2000 and to President and Chief Operating Officer in 2001. From 1993 to 1995, Dr. Jeffs worked at Burroughs Wellcome & Company where he was a member of the clinical research team that developed Flolan, the first FDA-approved therapy for patients with pulmonary arterial hypertension. From 1995 to 1998, Dr. Jeffs worked at Amgen, Inc. where he served as the worldwide clinical leader of the Infectious Disease Program. Dr. Jeffs currently leads the global clinical, commercial, manufacturing and business development efforts. |
Christopher Patusky |
Professor Christopher Patusky is Lead Independent Vice Chairman of the Board of United Therapeutics Corp. From August 2007 until July 2011, Professor Patusky served as Director, Office of Real Estate, for the Maryland Department of Transportation, where he was responsible for overseeing the Department's real estate matters statewide, including its transit-oriented development program. He continues to provide services to the Maryland Department of Transportation on real estate matters as an independent consultant. From 2002 until May 2007, Professor Patusky served as the Executive Director and a member of the faculty of the Fels Institute of Government at the University of Pennsylvania. From 1989 until 2000, Professor Patusky practiced law, focusing on litigation, intellectual property law and business startups. He has served as a United Therapeutics director since 2002. He is Management Consultant, Patusky Associates, LLC, Former Director, Office of Real Estate, Maryland Department of Transportation. |
John Ferrari |
Mr. John M. Ferrari is Chief Financial Officer, Treasurer of United Therapeutics Corp. He joined United Therapeutics in May 2001 as Controller. Mr. Ferrari was promoted to Vice President of Finance in December 2003 and to Vice President of Finance and Treasurer in June 2004. In August 2006, Mr. Ferrari was promoted to Chief Financial Officer and Treasurer. Prior to joining United Therapeutics, Mr. Ferrari served as Controller for Blackboard, Inc., from 1998 to 2001. Prior to his employment with Blackboard, Inc., Mr. Ferrari served in various senior financial management positions since beginning his accounting career in 1984. |
Paul Mahon |
Mr. Paul A. Mahon, J.D. is an Executive Vice President, General Counsel, Corporate Secretary of United Therapeutics Corp. He has served as General Counsel and Corporate Secretary of United Therapeutics since its inception in 1996. In June 2001, Mr. Mahon joined United Therapeutics full-time as Senior Vice President, General Counsel and Corporate Secretary. In November 2003, Mr. Mahon was promoted to Executive Vice President, General Counsel and Corporate Secretary. Prior to June 2001, he served United Therapeutics, beginning with its formation in 1996, in his capacity as principal and managing partner of a law firm specializing in technology and media law. |
Raymond Dwek |
Professor Raymond Dwek is a Director of United Therapeutics Corp. He is a Fellow of the Royal Society, London, and has served as Director of the Glycobiology Institute and Professor of Glycobiology at the University of Oxford since 1988. He was President of the Institute of Biology (a professional organization) from 2008 through 2010. From 2000 to 2006, Professor Dwek served as head of the Department of Biochemistry at the University of Oxford. Professor Dwek has been serving in positions at the University of Oxford since 1966. In 1988, Professor Dwek was the scientific founder of Oxford GlycoSciences PLC, which was publicly traded on the London Stock Exchange and NASDAQ, and he served as a member of its Board of Directors until its sale in 2003. He was the 2007 Kluge Chair of Technology and Society at the U.S. Library of Congress. Professor Dwek is the founder of glycobiology, the study of the structure, biosynthesis and biology of sugar chains attached to proteins. He has served as a United Therapeutics director since 2002. |
Raymond Kurzweil |
Mr. Raymond C. Kurzweil, J.D., M.G.A. is Non-Independent Director of United Therapeutics Corp. Mr. Kurzweil is an inventor, entrepreneur and author, and has created several important technologies in the artificial intelligence field. He has received the National Medal of Technology, the MIT-Lemelson Prize, nineteen honorary doctorates and honors from three U.S. Presidents. Mr. Kurzweil was selected as a 2002 inductee into the National Inventors Hall of Fame. Since 1995, Mr. Kurzweil has served as the Chief Executive Officer of Kurzweil Technologies, Inc., a technology development firm. He has served as a United Therapeutics director since 2002. He is a Director of Engineering, Google Inc. |
Christopher Causey |
Mr. Christopher Causey is an Independent Director of United Therapeutics Corp. Mr. Causey has served as the Principal of the Causey Consortium, a professional services organization providing business strategy and marketing counsel to the healthcare industry, since 2002. Previously, Mr. Causey served as a senior marketing officer for a variety of healthcare and technology companies. From 2001 to 2002, Mr. Causey served as the Chief Marketing Officer for Definity Health Incorporated. Since 2008, he has also been a member of the Board of Directors of Data Sciences International, Inc., a private company that develops wireless physiological monitoring solutions. Mr. Causey has served as a United Therapeutics director since 2003. |
Richard Giltner |
Mr. Richard Giltner is an Independent Director of United Therapeutics Corp. From 2009 until his retirement in 2010, Mr. Giltner was a portfolio manager at Lyxor Asset Management, an asset management group at the French bank Société Générale. From 2006 until 2009, he served as a managing director of Société Générale Asset Management, an international fund management firm, and head of the European office for its fund of hedge funds group. From 2003 to 2006, Mr. Giltner was the global head of foreign exchange options for the investment banking arm of Société Générale. He held other managerial positions within Société Générale from 1991 until 2003. Mr. Giltner has been a private investor since his retirement from Société Générale in 2010. He has served as a United Therapeutics director since 2009. |
R. Paul Gray |
Mr. R. Paul Gray is an Independent Director of United Therapeutics Corp. Mr. Gray is the Managing Member of Core Concepts, LLC, a strategic and financial consulting firm, which he founded in 2002. From 1985 to 1999, Mr. Gray practiced as a Certified Public Accountant at Ernst & Young LLP, KPMG LLP and Beers & Cutler LLP. Mr. Gray has served as an officer for his clients and companies within Core Concepts' portfolio from time to time. Mr. Gray serves on the boards of several public companies including Red Branch Technologies, Inc. (since 2006), Critical Solutions, Inc. (since 2009), and Biomimix, Inc. (since 2006). Mr. Gray serves on the board of Nano Therapies, LLC. Mr. Gray served on the board of TenthGate, Inc., a public medical holding company, until December 2007 and served as a director of Earth Search Sciences, Inc., a publicly traded company, until May 2005. Mr. Gray has served as a United Therapeutics director since 2003. |
Louis Sullivan |
The Hon. Dr. Louis W. Sullivan is an Independent Director of United Therapeutics Corp. Dr. Sullivan serves as a Director of Henry Schein, Inc. (since 2001), BioSante Pharmaceuticals, Inc. (since 1994), and Emergent BioSolutions, Inc. (since 2005), all publicly traded companies. Dr. Sullivan served on the boards of directors of a wide range of public companies, including General Motors Company, Bristol-Myers Squibb Company, Cigna Corporation, 3M Company and Georgia Pacific Corporation. Dr. Sullivan was the founding President of Morehouse School of Medicine, from 1981 to 1989, served as President again from 1993 to 2002, and became President Emeritus in July 2002. Dr. Sullivan was one of the founders and served as Chairman of Medical Education for South African Blacks, Inc., a member of the National Executive Council for the Boy Scouts of America, and a member of the Board of Trustees of Little League of America. Dr. Sullivan served as Secretary of the United States Department of Health and Human Services from 1989 to 1993. He is a physician certified in internal medicine with a subspecialty certification in hematology. He has served as a United Therapeutics director since 2002. |
Tommy Thompson |
Gov. Hon.Tommy G. Thompson is an Independent Director of United Therapeutics Corp. Before entering the private sector in 2005, Governor Thompson enjoyed a long and distinguished career in public service. As Secretary of Health and Human Services from 2001 to 2005, he was a advocate for the health and welfare of all Americans. He served four terms as Governor of Wisconsin from 1987 to 2001. From 2005 until January 2012, Governor Thompson served as a partner at the law firm of Akin Gump Strauss Hauer & Feld LLP in Washington, D.C. From 2005 to 2009, he served as the Independent Chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of nation's pressing health care and public health related challenges. He served as chairman of the board of directors of AGA Medical Holdings, Inc. from 2005 until November 2010, and is a member of the boards of directors of CareView Communications, Inc., Centene Corporation, C.R. Bard, Inc., Cytori Therapeutics, Inc. He previously served on the boards of directors of SpectraScience and CNS Response, Inc. (through December 2009), and X Shares Advisors (through March 2007). He has served as a United Therapeutics director since 2010. He is Former Secretary, U.S. Department of Health and Human Services. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Martine Rothblatt |
3,161,350 |
Roger Jeffs |
4,782,540 |
Christopher Patusky |
-- |
John Ferrari |
3,401,390 |
Paul Mahon |
3,618,660 |
Raymond Dwek |
-- |
Raymond Kurzweil |
-- |
Christopher Causey |
-- |
Richard Giltner |
-- |
R. Paul Gray |
-- |
Louis Sullivan |
-- |
Tommy Thompson |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Martine Rothblatt |
1,814,456 | 45,696,606 |
Roger Jeffs |
630,506 | 21,781,370 |
Christopher Patusky |
0 | 0 |
John Ferrari |
170,220 | 4,422,200 |
Paul Mahon |
437,335 | 9,924,060 |
Raymond Dwek |
0 | 0 |
Raymond Kurzweil |
0 | 0 |
Christopher Causey |
0 | 0 |
Richard Giltner |
0 | 0 |
R. Paul Gray |
0 | 0 |
Louis Sullivan |
0 | 0 |
Tommy Thompson |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
MAHON PAUL A |
6,000 | $68.05 |
FERRARI JOHN MAXIM |
4,500 | $68.48 |
JEFFS ROGER A |
10,000 | $25.32 |
JEFFS ROGER A |
10,000 | $65.81 |
PATUSKY CHRISTOPHER |
3,500 | $66.75 |
FERRARI JOHN MAXIM |
9,000 | $33.14 |
MAHON PAUL A |
6,000 | $30.75 |
PATUSKY CHRISTOPHER |
3,500 | $31.17 |
DWEK RAYMOND ALLEN |
3,000 | $27.70 |
CAUSEY CHRISTOPHER |
1,500 | $66.75 |
CAUSEY CHRISTOPHER |
1,500 | $31.17 |
FERRARI JOHN MAXIM |
9,000 | $67.17 |
DWEK RAYMOND ALLEN |
3,000 | $66.75 |
MAHON PAUL A |
6,000 | $67.15 |
JEFFS ROGER A |
10,000 | $25.32 |
JEFFS ROGER A |
10,000 | $60.26 |
MAHON PAUL A |
6,000 | $30.75 |
MAHON PAUL A |
6,000 | $59.93 |
DWEK RAYMOND ALLEN |
3,000 | $27.70 |
DWEK RAYMOND ALLEN |
6,000 | $22.57 |
DWEK RAYMOND ALLEN |
9,000 | $61.35 |
JEFFS ROGER A |
3,250 | $60.01 |
JEFFS ROGER A |
6,750 | $60.01 |
JEFFS ROGER A |
3,250 | $25.32 |
JEFFS ROGER A |
6,750 | $25.32 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
